12:00 AM
 | 
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

AeroVanc: Phase Ib data

Top-line data from 6 non-MRSA infected CF patients in the Phase Ib portion of an open-label, Australian Phase Ia/Ib trial showed that single doses of 32 and 80 mg...

Read the full 124 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >